{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rDEN3%CE%9430",
    "query": {
      "intervention": "rDEN3Δ30"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rDEN3%CE%9430&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T07:08:57.672Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06805487",
      "title": "Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Zika Virus"
      ],
      "interventions": [
        {
          "name": "TetraVax-DV-TV003 (TV003)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasmalyte",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Challenge virus ZIKV-SJRP/2016-184",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 27,
      "start_date": "2024-09-24",
      "completion_date": "2025-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06805487"
    },
    {
      "nct_id": "NCT02433652",
      "title": "Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "Recombinant live attenuated trivalent dengue vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN2Δ30-7169 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-02-28",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02433652"
    },
    {
      "nct_id": "NCT01436422",
      "title": "Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "TetraVax-DV Vaccine - Admixture TV003",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TetraVax-DV Vaccine - Admixture TV005",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 112,
      "start_date": "2011-08",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2015-08-20",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01436422"
    },
    {
      "nct_id": "NCT02879266",
      "title": "Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "TetraVax-DV TV005",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "50 Years to 70 Years"
      },
      "enrollment_count": 28,
      "start_date": "2016-02-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-04-02",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02879266"
    },
    {
      "nct_id": "NCT01072786",
      "title": "Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "TetraVax-DV Vaccine-Admixture 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TetraVax-DV Vaccine-Admixture 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TetraVax-DV Vaccine-Admixture 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TetraVax-DV Vaccine-Admixture 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TetraVax-DV Vaccine-Admixture 5",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 141,
      "start_date": "2010-07",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2013-01-03",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072786"
    },
    {
      "nct_id": "NCT05691530",
      "title": "Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Response To Dengue Exposure"
      ],
      "interventions": [
        {
          "name": "rDEN3Δ30/31-7164",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 127,
      "start_date": "2023-03-07",
      "completion_date": "2025-10-27",
      "has_results": true,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05691530"
    },
    {
      "nct_id": "NCT01506570",
      "title": "Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "TetraVax-DV Vaccine - Admixture TV003",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TetraVax-DV Vaccine - Admixture TV005",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 58,
      "start_date": "2011-12",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2015-08-20",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01506570"
    },
    {
      "nct_id": "NCT03416036",
      "title": "Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "TetraVax-DV-TV003 (TV003)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN2Δ30-7169 (DENV-2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN3Δ30 (DENV-3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2017-11-28",
      "completion_date": "2019-06-04",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03416036"
    },
    {
      "nct_id": "NCT02684383",
      "title": "Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "rDEN3∆30",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 14,
      "start_date": null,
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-30",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02684383"
    },
    {
      "nct_id": "NCT02873260",
      "title": "Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "TetraVax-DV-TV005",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN3Δ30",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-08",
      "completion_date": "2017-11",
      "has_results": false,
      "last_update_posted_date": "2018-03-08",
      "last_synced_at": "2026-09-17T07:08:57.672Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02873260"
    }
  ]
}